Javascript required
Skip to content Skip to sidebar Skip to footer
Home / Countries Where Biologic Therapy for Lupus Is Not Financed

Countries Where Biologic Therapy for Lupus Is Not Financed

doi: 10.5114/reum.2015.51507. Epub 2015 May 18.

Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008-2012

Affiliations

  • PMID: 27407232
  • PMCID: PMC4847273
  • DOI: 10.5114/reum.2015.51507

Free PMC article

Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008-2012

Andrzej Śliwczyński  et al. Reumatologia. 2015 .

Free PMC article

Abstract

Objectives: The goal of the article is to present the changes in morbidity and costs of systemic lupus erythematosus (SLE) in Poland in the 2008-2012 period, depending on the province of residence of the patients based on data reported to the public payer - the National Health Fund.

Material and methods: Based on the ICD-10 code and the patient's personal identity number, the number of patients and medical costs (cost of hospitalization, pharmaceutical, medical procedures, dialysis and specialist consultations) were calculated by province (voivodeship) and urban or rural residence.

Results: Annually on average in the assessed period in Poland approximately 20 000 patients were diagnosed with SLE. The studied group was dominated by women (they were 5.2 times more numerous). The morbidity rate was 52.183 patients per 100 thousand inhabitants. Most patients were in the age range of 48-56 years. Average annual expenses for this group of patients over the examined period were USD 16,327 million. Two times more was expended on patients inhabiting cities, approximately 4 times more on women. Calculated per patient, the average cost of therapy was USD 810.63.

Conclusions: The population of SLE patients in Poland is highly stable. The results of analysis indicate 1.64 times more frequent occurrence in urban areas, which may be connected with availability of doctors. The SLE treatment costs in Poland are much lower than in other countries, which is related mainly to the fact that therapy with biological drugs is not financed.

Keywords: epidemiology; health economics; regional differences; systemic lupus erythematosus.

Figures

Fig. 1
Fig. 1

Age structure of SLE patients hospitalised in Poland for the 2008–2012 period.

Fig. 2
Fig. 2

Morbidity and reimbursement per 100,000 population.

Similar articles

  • Epidemiology of Rheumatoid Arthritis (RA) in rural and urban areas of Poland - 2008-2012.

    Iltchev P, Śliwczyński A, Czeleko T, Sierocka A, Tłustochowicz M, Tłustochowicz W, Timler D, Brzozowska M, Szatko F, Marczak M. Iltchev P, et al. Ann Agric Environ Med. 2016 Jun 2;23(2):350-6. doi: 10.5604/12321966.1203904. Ann Agric Environ Med. 2016. PMID: 27294646

  • Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.

    Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Li T, et al. Arthritis Rheum. 2009 Jun 15;61(6):755-63. doi: 10.1002/art.24545. Arthritis Rheum. 2009. PMID: 19479688

  • Epidemiology of asthma in Poland in urban and rural areas, based on provided health care services.

    Śliwczyński A, Brzozowska M, Iltchew P, Czeleko T, Kucharczyk A, Jędrzejczyk T, Jahnz-Różyk K, Marczak M. Śliwczyński A, et al. Pneumonol Alergol Pol. 2015;83(3):178-87. doi: 10.5603/PiAP.2015.0029. Pneumonol Alergol Pol. 2015. PMID: 26050977

  • The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland.

    Kawalec PP, Malinowski KP. Kawalec PP, et al. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):667-73. doi: 10.1586/14737167.2015.1065733. Epub 2015 Jul 7. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 26153642 Review.

  • A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.

    Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, Goss TF. Slawsky KA, et al. Arthritis Care Res (Hoboken). 2011 Sep;63(9):1224-32. doi: 10.1002/acr.20502. Arthritis Care Res (Hoboken). 2011. PMID: 21584945 Review.

Cited by 3 articles

  • Lack of Association between Serum Interleukin-23 and Interleukin-27 Levels and Disease Activity in Patients with Active Systemic Lupus Erythematosus.

    Pawlak-Buś K, Schmidt W, Leszczyński P. Pawlak-Buś K, et al. J Clin Med. 2021 Oct 19;10(20):4788. doi: 10.3390/jcm10204788. J Clin Med. 2021. PMID: 34682911 Free PMC article.

  • Systemic Lupus Erythematosus, Its Impact on Selected Cardiovascular Risk Factors, and Correlation with Duration of Illness: A Pilot Study.

    Przywara-Chowaniec B, Blachut D, Harpula J, Bereś M, Nowak A, Nowalany-Kozielska E. Przywara-Chowaniec B, et al. Cardiol Res Pract. 2020 Nov 5;2020:7025329. doi: 10.1155/2020/7025329. eCollection 2020. Cardiol Res Pract. 2020. PMID: 33204527 Free PMC article.

  • Differences in selected medical care parameters in rheumatic disease ward patients of different ages of life.

    Pobrotyn P, Susło R, Witczak I, Milczanowski P, Drobnik J. Pobrotyn P, et al. Reumatologia. 2016;54(2):54-60. doi: 10.5114/reum.2016.60213. Epub 2016 Jun 3. Reumatologia. 2016. PMID: 27407280 Free PMC article.

References

    1. Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012;51:157–168. - PubMed
    1. Aghdassi E, Zhang W, St-Pierre Y, et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol. 2011;38:658–666. - PubMed
    1. Pelletier EM, Ogale S, Yu E, et al. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a us claims database. Clin Ther. 2009;31:2653–2664. - PubMed
    1. Lateef A, Petri M. Biologics in the treatment of systematic lupus erythematosus. Curr Opin Rheumatol. 2010;22:504–509. - PubMed
    1. WHO guide to identifying the economic consequences of disease and injury. World Health Organization; 2009. online: http://www.who.int/choice/publications/d_economic_impact_guide.pdf (accessed 20 January 2014)

LinkOut - more resources

  • Full Text Sources

    • Europe PubMed Central
    • PubMed Central
    • Termedia Publishing House Ltd.

  • Other Literature Sources

    • scite Smart Citations

Countries Where Biologic Therapy for Lupus Is Not Financed

Source: https://pubmed.ncbi.nlm.nih.gov/27407232/